Trump Administration to Implement Pharmaceutical Tariffs on Select Drugmakers

The Trump administration is preparing to impose tariffs, potentially reaching up to 100%, on branded drugs imported from pharmaceutical companies that have not negotiated agreements to lower U.S. Drug prices. This move represents a continuation of President Trump’s aggressive trade strategy and a renewed focus on bringing pharmaceutical manufacturing back to the United States.

Details of the Proposed Tariffs

According to a draft document reported by CNBC, patented medications and their active ingredients could face a 100% tariff. However, pharmaceutical companies can mitigate or avoid these levies by relocating their manufacturing to the U.S. Or by reaching agreements with the administration to lower drug prices. The proposal, while not yet finalized, could be announced as early as Thursday, April 2, 2026.

“Most Favored Nation” Policy

The tariffs are linked to the administration’s “Most Favored Nation” policy, which aims to secure lower drug prices through direct negotiations with manufacturers. Over a dozen major drugmakers, including Eli Lilly, Pfizer, and Novo Nordisk, have already entered into agreements with the Trump administration to lower the prices of both new and existing medicines.

Background and Context

This plan marks another shift in Trump’s trade strategy, coming more than a month after the Supreme Court struck down his global levies imposed in 2025, which had previously excluded the pharmaceutical industry. The administration’s approach incentivizes companies to negotiate deals or establish production facilities within the U.S.

Reshoring American Manufacturing

The push for pharmaceutical tariffs aligns with Trump’s broader economic agenda of reshoring American manufacturing and reducing reliance on foreign-made goods. This goal gained increased urgency following supply chain disruptions experienced during the COVID-19 pandemic.

Potential Impact

The announcement is expected to have significant repercussions for global pharmaceutical markets, potentially raising concerns among investors, healthcare providers, and consumers regarding drug pricing and supply availability. Analysts suggest that increased import costs could be passed on to patients, further complicating the U.S. Healthcare system.